In a phase 2, multicenter, randomized, placebo controlled double blind study, crizanlizumab with or without hydroxyurea (SUSTAIN study) (ClinicalTrails.gov Identifier: NCT01895361) showed that patients on the treatment arm had significantly lower rate of sickle-related pain crises compared to placebo with a lower incidence of adverse events - 10% of patients suffered from moderate side effects while one patient suffered from an intracranial bleed during treatment with this drug that could also interfere with platelet function via its effects on selectins ( Post hoc analyses showed that more patients were VOC event-free in the crizanlizumab arm than in the placebo arm, and that crizanlizumab also significantly increased time-to-first VOC compared to the placebo (Kutlar et al., 2019)
Here's what most people miss: it needs physical activity to do its job
We also track true body compositionnot just weightso you can see meaningful changes in fat loss, muscle preservation, and overall metabolic health
Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ
[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Mateen S, Zafar A, Moin S, Khan AQ, Zubair S